Short-duration therapy for hepatitis C: Suitable for all?

Journal of Viral Hepatitis

Volumn 14, Issue 4, 2007, Pages 221-227

  Mangia, A ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

HCV genotype; PegIFN ; Ribavirin; RVR

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 33947385041     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00817.x     Document Type: Review

References (34)

1. Perz JF, Farr ington LA, Pecoraro C, Hutin YJ, Armstrong GL. Estimated global prevalence of hepatitis C virus infection A357. J Infect Dis 2004; 154.
2. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind placebo-controlled trial. N Engl J Med 1989; 22: 1506-1510.
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
4. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
5. Fried MW, Shiffaman ML, Reddy KR et al. Peginterferon alpfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
7. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235.
8. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85: 3173-3188.
9. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
10. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
11. Hultgren C, Desombere I, Leroux-Roels G et al. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004; 40: 971-978.
12. Tang KH, Herrmann E, Cooksley H et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005; 43: 776-782.
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peg-interferon alfa 2b plus ribavirin inn patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
14. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa 2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433.
15. Jensen D, Morgan T, Marcellin P et al. Rapid virologic response at week 4 (RVR) of peginterferon alfa 2a (40KD) plus ribavirin treatment predicts sustained virological response (SVR) after 24 weeks in genotype 1 patients. Hepatology 2006; 43: 954-960.
16. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon- α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
17. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with genotypes 2 or 3. J Hepatol 2004; 40: 993-999.
18. Mangia A, Santoro R, Mnerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
19. Dalgard O, Bjoro K, Hellman KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 41: 1260-1263.
20. von Wagner M, Huber M, Berg T et al. Peginterferon alfa 2a (40 kd) and ribavirin for 16 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.
21. Shiffman ML, Pappas S, Nyberg L et al. Peginteferon alfa-2a (pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV Genotype 2 or 3. Final results of the ACCELERATE trial. J Hepatol 2006; 44: S271.
22. Ferenci P, Bergholz U, Laferl H et al. Steindl-Munda. 24 week treatment regimen with Peginterferon alfa 2a (40 KD) (Pegasys) plus Ribavirin (Copegus) in HCV genotype 1 or 4 'super-responders'. J Hepatol 2006; 44: 56.
23. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa 2b plus ribavirin in patients with chronic hepatitis C infection with genotype 1 and low pre- treatment viremia. J Hepatol 2006; 44: 97-103.
24. Bruno S, Camma C, Di Marco V et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-481.
25. Andriulli A, Dalgard O, Bjioro K, Mangia A. Short term treatment duration for HCV-2 and HCV-3 infected patients. Dig liver dis 2006; 38: 741-748.
26. Rizzetto M. treatment of hepatitis c virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005; 42: 275-278.
27. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999; 31: 237-243.
28. Di Marco V, Ferraro D, Almasio P et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepat 2002; 9: 354-359.
29. Terrault NA, Pawlotsky JM, McHutchison J et al. Clinical utility of viral load misurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral hepat 2005; 12: 465-472.
30. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alpha 2a. J Hepatol 2002; 37: 500-506.
31. Pockros PJ, Carithers R, Desmond P et al. Efficacy and safety of two-dose regimens of peginterferon alpha2a compared with interferon alpha 2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-1305.
32. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa 2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
33. Reddy K, Rakela J, Lopez-Talavera J, Pockros PJ. Correlation between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients with pegylated interferon alfa 2a and ribavirin. Gastroenterology 2005; 128: S1540.
34. Ferenci P, Shifffman M, Fried M et al. Early prediction of response to 40KD peginteferon alfa-2a (PEGASYS) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001; 34: 351A.